Clinical Trial Detail

NCT ID NCT04187833
Title Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Case Comprehensive Cancer Center
Indications

melanoma

Therapies

Nivolumab + Talazoparib

Age Groups: adult senior

Additional content available in CKB BOOST